Speakers:
Amrita Krishnan, MD, City of Hope
,
Sagar Lonial, MD, Winship Cancer Institute, School of Medicine, Emory University
,
Robert Z. Orlowski, MD, PhD, The University of Texas MD Anderson Cancer Center
,
Noopur Raje, MD, Massachusetts General Hospital Cancer Center
and
Paul G. Richardson, MD, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School
Disclosures:
Krishnan: Bristol-Myers Squibb Company: Other: Stock Options/Ownership-Public Company; Janssen Biotech Inc: Other: Contracted Research; Amgen Inc, Bristol-Myers Squibb Company, Takeda Pharmaceuticals USA Inc: Other: Speakers Bureau; Adaptive Biotechnologies Corporation, Bristol-Myers Squibb Company, GlaxoSmithKline, Regeneron Pharmaceuticals Inc, Sanofi Genzyme: Other: Consulting Agreements; Sutro Biopharma: Other: Advisory Committee. Lonial: Bristol-Myers Squibb Company, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc.: Other: Contracted Research, Research Funding; Janssen: Research Funding; AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Pfizer Inc, Takeda Pharmaceuticals USA Inc: Consultancy, Other: Advisory Committee; TG Therapeutics Inc: Other: Board of Directors with Stock; Novartis: Research Funding. Orlowski: Asylia Therapeutics, BioTheryX Inc., Heidelberg Pharma: Other: Laboratory Research Funding, Research Funding; Asylia Therapeutics: Current equity holder in private company, Patents & Royalties; BMS/Celgene Corporation, CARsgen Therapeutics, Exelixis Inc., Heidelberg Pharma, Janssen Biotech Inc., Sanofi/Genzyme, Takeda Pharmaceuticals USA Inc.: Other: Clinical Research Funding, Research Funding; AbbVie, Adaptive Biotech, Asylia Therapeutics, Inc., BioTheryX, Bristol-Myers Squibb Pharmaceuticals, Karyopharm Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, Nanjing IASO Biotherapeutics, Neoleukin Corporation, Oncopeptides AB, Pfizer, In: Consultancy, Honoraria. Raje: Amgen Inc, Roche Laboratories Inc.: Other: Steering Committee; bluebird bio: Other: Contracted Research; bluebird bio, Bristol-Myers Squibb Company, Caribou Biosciences Inc, Celgene Corporation, Immuneel Therapeutics, Janssen Biotech Inc, Merck, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Pharmaceuticals USA Inc: Other: Advisory Committee. Richardson: Celgene Corporation: Consultancy, Research Funding; Karyopharm Therapeutics: Consultancy, Research Funding; GlaxoSmithKline: Consultancy, Research Funding; Takeda Pharmaceuticals USA Inc: Consultancy, Research Funding; Oncopeptides: Consultancy, Research Funding; Sanofi: Consultancy; GSK: Consultancy; Bristol-Myers, Squibb Company: Consultancy, Research Funding.
On Demand program will be available here soon. For questions, please reach out to the managing company contact from Research to Practice, listed below.
This CME-accredited program, offered for in-person and virtual attendees, will focus on the management of multiple myeloma (MM). Five investigators will serve as faculty and the program will be moderated by Dr Neil Love, president of Research To Practice (RTP). Prior to the program, RTP will recruit 15 clinical investigators, who, in addition to the participating faculty, will be asked to complete a case-based survey intended to illuminate their general practice patterns. In addition, RTP will recruit 3 “non-faculty” clinical investigators to participate in video recorded interviews with Dr Neil Love in which they will provide an explanation/justification for their responses to this survey and share the scientific rationale guiding their thinking.
At the live event, for each module, Dr Love will present results from the case-based survey, followed by video excerpts from the non-faculty member interviews. The faculty panel will then be asked to register their level of agreement/disagreement with their colleagues’ answers and provide perspectives on their own responses. Each faculty member will also deliver a brief PPT presentation focused on reviewing recently published research data and ongoing clinical trials. Clinicians in attendance will have to complete the same survey and present their own questions for discussion.
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.